Detection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 (T1R) reactions.

International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association Pub Date : 2004-03-01 DOI:10.1489/1544-581X(2004)072<0027:DOIIAI>2.0.CO;2

Sara E Atkinson, Saroj Khanolkar-Young, Sharon Marlowe, Suman Jain, Raj Gopal Reddy, Sujai Suneetha, Diana N J Lockwood

{"title":"Detection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 (T1R) reactions.","authors":"Sara E Atkinson, Saroj Khanolkar-Young, Sharon Marlowe, Suman Jain, Raj Gopal Reddy, Sujai Suneetha, Diana N J Lockwood","doi":"10.1489/1544-581X(2004)072<0027:DOIIAI>2.0.CO;2","DOIUrl":null,"url":null,"abstract":"<p><p>This study demonstrates the presence of IL-10 and IL-6, by immunohistochemistry, in the skin lesions of patients with Type 1 reactions. Fifteen patients with Type 1 reaction from Hyderabad, India were included in this study. They were all receiving standardized treatment for Type 1 reactions: a reducing course of daily oral prednisolone for 6 months. Biopsies were taken before treatment and during treatment at weeks 1, 4, and 6 months. IL-13 was observed in the lesions of most patients. By week 4 of treatment, the presence of IL-13, IL-10, and IL-6 in the lesions had decreased significantly. Although some patients showed significant clinical skin sign improvement within one week of therapy, no concomitant decrease or increase in any of the cytokines was observed at this time point. Interestingly, some cytokine activity within the lesions was observed after 6 months of treatment.</p>","PeriodicalId":14078,"journal":{"name":"International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association","volume":"72 1","pages":"27-34"},"PeriodicalIF":0.0000,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1489/1544-581X(2004)072<0027:DOIIAI>2.0.CO;2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

Abstract

This study demonstrates the presence of IL-10 and IL-6, by immunohistochemistry, in the skin lesions of patients with Type 1 reactions. Fifteen patients with Type 1 reaction from Hyderabad, India were included in this study. They were all receiving standardized treatment for Type 1 reactions: a reducing course of daily oral prednisolone for 6 months. Biopsies were taken before treatment and during treatment at weeks 1, 4, and 6 months. IL-13 was observed in the lesions of most patients. By week 4 of treatment, the presence of IL-13, IL-10, and IL-6 in the lesions had decreased significantly. Although some patients showed significant clinical skin sign improvement within one week of therapy, no concomitant decrease or increase in any of the cytokines was observed at this time point. Interestingly, some cytokine activity within the lesions was observed after 6 months of treatment.

查看原文本刊更多论文

强的松龙治疗1型(T1R)反应患者麻风皮损中IL-13、IL-10和IL-6的检测

本研究通过免疫组织化学证实了IL-10和IL-6在1型反应患者皮肤病变中的存在。来自印度海得拉巴的15例1型反应患者被纳入本研究。他们都接受了1型反应的标准化治疗:每天口服强的松龙6个月，疗程减少。分别于治疗前、治疗第1周、第4周和第6周进行活检。大多数患者的病变中均可见IL-13。到治疗第4周时，病变中IL-13、IL-10和IL-6的含量明显降低。虽然一些患者在治疗一周内表现出明显的临床皮肤体征改善，但在此时间点未观察到任何细胞因子的减少或增加。有趣的是，治疗6个月后观察到病变内的一些细胞因子活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association

自引率

0.00%

发文量